Nosocomial infections caused by extensively drug resistant (XDR) nosocomial Pseudomonas aeruginosa isolates is a problem of great concern of current health care. The aim of this study was to evaluate current resistance rates of P. aeruginosa in Minsk hospitals and to describe risk factors of extensively drug resistant pseudomonal infection. The current rates of P. aeruginosa resistance to antibiotics were: ceftazidime - 64,0%, ciprofloxacin - 96,5%, gentamycin - 84,9%, amikacyn - 84,9%, imipinem - 72,1%, meropenem - 62,8%, polymyxins — 0%. The main risk factors of XDR P.aeruginosa acqusition were hospitalisation from other hospitals, multiple recovery of P.aeruginosa isolates in current hospitalisation and use of metronidazole in previous 6 months. This data may be helpful in estimation the risk of acquisition of nosocomial extensively drug resistant pseudomonal infection and in selection of appropriate empirical antibacterial therapy.
- 1. Эйдельштейн, М.В. et al. Распространенность и молекулярная эпидемиология грамотрицательных бактерий, продуцирующих металло-беталактамазы, в России, Беларуси и Казахстане / М.В. Эйдельштейн et al. // Клиническая микробиология и антимикробная химиотерапия. - 2012. -Том 14, № 2 . - С . 132-153.
- 2. Aloush, V. et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact / V. Aloush et al. // Antimicrobial Agents and Chemotherapy. - 2006. - Vol. 50, № 1. - P. 43-48.
- 3. Cipriano Souza, R. et al. Clindamycin and metronidazole as independent risk factors for nosocomial acquisition of multidrug-resistant Pseudomonas aeruginosa / R. Cipriano Souza et al. //The Journal of hospital infection. - 2008. - Vol. 69, № 4. - P. 402-403.
- 4. Cornaglia, G. Giamarellou, H. & Rossolini, G.M. Metallo-β-lactamases: a last frontier for β-lactams? / G. Cornaglia, H. Giamarellou, G.M. Rossolini // The Lancet Infectious Diseases. - 2011. - Vol. 11, № 5. - P. 381-393.
- 5. Magiorakos A-P, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance / A-P Magiorakos et al. // Clinical Microbiology and Infection. - 2012. - Vol. 18, № 3. - P. 268-281.
- 6. Hirsch, E.B. & Tam, V.H. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes / E.B. Hirsch, V.H. Tam // Expert Review of Pharmacoeconomics & Outcomes Research. - 2010. - Vol. 10, № 4. - P. 441-451.
- 7. Lambert, M.-L. et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study / M.-L. Lambert et al. // The Lancet Infectious Diseases. - 2011. - Vol. 11, № 1. - P. 30-38.
- 8. Lautenbach, E. et al. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes / E. Lautenbach et al. // Infection Control and Hospital Epidemiology. - 2006. - Vol. 27, № 9. - P. 893-900.
- 9. Llanes, C. et al. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously / C. Llanes et al. // Antimicrobial Agents and Chemotherapy. - 2004. - Vol. 48, № 5. - P. 1797-1802.
- 10. Masuda, N. et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexW-oprM efflux pumps in Pseudomonas aeruginosa / N. Masuda et al. // Antimicrobial Agents and Chemotherapy. - 2000. - Vol. 44, № 12. - P. 3322-3327.
- 11. Talon, D. et al. Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa / D. Talon et al. // American journal of respiratory and critical care medicine. - 1998. - Vol. 157, № 3 pt 1. - P. 978-984.